Monday , February 19 2018

Recent Posts

FDA Accepts Theravance and Mylan’s NDA for Revefenacin for the Treatment of Adults with COPD

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ, TASE: MYL) (“Mylan”) …

Read More »